Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma.
Maruyama
Katsuhiko
K
Shirato
Shiroaki
S
Haneda
Mai
M
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D011799:Quinazolines; D000077338:Latanoprost; C018176:bunazosin